CPC G16H 20/17 (2018.01) [G16C 20/30 (2019.02); G16H 50/20 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01); A61K 49/0004 (2013.01); A61P 7/04 (2018.01); G06N 7/01 (2023.01); G16C 20/50 (2019.02); G16C 20/70 (2019.02)] | 13 Claims |
1. A method comprising:
determining, via a processor, an estimated pharmacokinetic (PK) profile of a patient using a Bayesian model of PK profiles of sampled patients;
determining, via the processor, a first dosing regimen for a first specified dosing interval in response to receiving at least one of a selected minimum therapeutic plasma protein level, a selected dosing interval, or a selected dosage amount of a therapeutic plasma protein, wherein:
the first dosing regimen is associated with a first time-varying therapeutic plasma protein level in the patient that is based at least upon the estimated PK profile, and
the at least one of the selected minimum therapeutic plasma protein level, the selected dosing interval, or the selected dosage amount is received at the processor via a graphical user interface (GUI) that includes fields for user input for adjusting at least one of the selected minimum therapeutic plasma protein level, the selected dosing interval, or the selected dosage amount; and
determining, via the processor, if the patient has a therapeutic plasma protein half-life greater than a predetermined threshold, wherein:
a first weighting factor is applied to the Bayesian model of PK profiles of sampled patients if the half-life of the patient is greater than the predetermined threshold, and
a second weighting factor, less than the first weighting factor, is applied to the Bayesian model of PK profiles of sampled patients if the half-life of the patient is less than the predetermined threshold.
|